Signals
3Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Vaping-associated lung disease as a recognised category
EVALI (e-cigarette and vaping-associated lung injury) and chronic bronchiolitis from vaping are now recognised pulmonology diagnostic categories.
Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Snapshots
3Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Obstructive sleep apnea therapy reference (2026)
Reference snapshot of OSA therapy across positive airway pressure, oral appliances, surgery, neurostimulation, and emerging pharmacotherapy.
Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
Explained
4What is allergic bronchopulmonary aspergillosis?
Plain-language primer on ABPA, why it is different from typical asthma, and how modern therapy works.
Severe COPD and biologic therapy explained
Plain-language primer on severe COPD, why biologic therapy is now an option for some patients, and what the modern combined approach can offer.
What is obstructive sleep apnea?
Plain-language primer on obstructive sleep apnea, why CPAP has been the standard, and what is changing in OSA therapy.
What is refractory chronic cough?
Plain-language primer on refractory chronic cough, why it is a distinct condition, and what is changing in therapy.